The earnings miss and widening loss are negative, but biotech valuations are driven by pipeline catalysts. Focus on TX45 APEX Phase 2 topline data (late Q4 2026/early Q1 2027) and TX2100 Phase 1a readout (Q3 2026). Cash runway into Q4 2028 provides no near-term dilution risk. Monitor for any protocol changes or safety signals in ongoing trials.
Price Chart
Executive Summary
Tectonic Therapeutic reported Q1 2026 net loss of $25.2M (-$1.34/share), missing consensus of -$1.16 by 15.5%. R&D spending increased 60% YoY to $20.9M, driven by clinical trial costs. Cash burn narrowed to $16.9M from prior quarter, with $236.9M cash runway into Q4 2028. Pipeline progress included TX45 APEX Phase 2 enrollment nearing completion and TX2100 Phase 1a four cohorts dosed.
Key Financial Metrics
Key Facts
- Net loss per share $-1.34 vs consensus $-1.16 (15.5% miss)
- Net loss widened to $25.2M from $15.9M year ago (59% increase)
- Cash and equivalents $236.9M, down $16.9M from Dec 2025
- R&D expenses $20.9M, up from $13.0M (60% YoY increase)
- TX45 APEX Phase 2 enrollment nearing completion, topline expected late 2026/early 2027
- TX2100 Phase 1a in healthy volunteers: 4 cohorts dosed, results expected Q3 2026
Financial Impact
Net loss per share miss of 15.5% vs consensus; R&D spend up 60% YoY; cash burn accelerated
Risk Factors
- Clinical trial failure (TX45 or TX2100)
- Higher-than-expected cash burn requiring secondary offering
- Competitive therapies for PH-HFpEF or HHT advancing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-212069 |
| Document: tecx-20260507.htm | 0001193125-26-212069 |
| Document: 0001193125-26-212069-index-headers.html | 0001193125-26-212069 |
| Document: 0001193125-26-212069-index.html | 0001193125-26-212069 |
| Document: 0001193125-26-212069.txt | 0001193125-26-212069 |
| 8-K Data (Synthetic) | 0001193125-26-212069 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 9w ago | 144 | $36.47 | awaiting T+60 | — | $20.34 (−44.23%) |
Jun 11, 2026 19w ago | Institutional Cluster | $29.34 $30.75 | ▲ +4.81% | ▲ +0.41% | $20.34 (−30.67%) |
May 7, 2026 24w ago | 8-K | $29.00 $29.17 | ▼ −0.59% | ▲ +4.25% | $20.34 (+29.86%) |
May 7, 2026 24w ago | Press Release | $29.00 $29.17 | ▲ +0.59% | ▼ −4.25% | $20.34 (−29.86%) |
Apr 24, 2026 26w ago | DEFA14A | $28.75 $31.59 | ▲ +9.88% | ▲ +5.10% | $20.34 (−29.25%) |
Apr 3, 2026 29w ago | 3 | $29.98 $32.74 | ▲ +9.21% | ▼ −4.26% | $20.34 (−32.15%) |
Mar 6, 2026 33w ago | Insider Cluster | $35.87 $28.89 | ▼ −19.46% | ▼ −32.24% | $20.34 (−43.30%) |
Feb 24, 2026 35w ago | 8-K | $23.11 $28.84 | ▲ +24.79% | ▲ +17.84% | $20.34 (−11.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers